Cartalax

What it is

Cartalax is one of the Khavinson bioregulators, a tiny peptide meant to nudge cartilage cells toward making more of their own matrix. People run it in courses of about 20 days (up to 30) for joints that grind and old injuries that never settled. The evidence is cell work from one institute, with no animal joint model, so the realistic expectation is a small, slow effect on top of a proper healing stack, not instead of one.

The people who buy Cartalax are usually over 40 with knees or hips that creak, a shoulder that was injured a decade ago, or early wear a scan has already shown. Most of them are already running BPC-157 and want something that speaks to cartilage specifically rather than tendon and gut. A second group is the longevity crowd doing a rotation of Khavinson peptides (Epitalon, Pinealon, Vilon) and adding the joint one to the set.

What to expect: not much that you can point to, and nothing fast. Cartilage does not regrow on a 20-day timeline, so the best honest report is a joint that feels a little less stiff first thing in the morning by the end of the course, and people who repeat it two or three times a year say that is when they notice a difference. If a knee is actively swollen and hot, Cartalax will not touch that. If you want something you can feel in a week, this is the wrong peptide.

The course is short on purpose. The tiers are 100, 200 and 300 mcg subQ once a day for about 20 days (up to 30), then a few months off before the next course, two or three courses a year, which is how the whole bioregulator family is used. The break is not about tolerance: the effect is meant to carry on for months after a course, so there is nothing to gain from running it straight through. A 20 mg vial is far more than one course: 20 days at 200 mcg uses 4 mg, so most of a mixed vial outlives its 3 to 4 week fridge life. The common mistakes are running it for months like a vendor sheet suggests, and buying it instead of BPC-157 rather than alongside it.

Evidence sits at animal 0, human 0 by our grading. What exists is cell-culture and gene-expression work from the St. Petersburg Institute of Bioregulation and Gerontology, where it was shown to raise markers of cartilage matrix building (type II collagen, aggrecan) in chondrocytes and to lower a matrix-degrading enzyme, MMP-9. That is a plausible story and a small one. No animal joint model, no human trial, and nothing replicated outside that network.

Not worth it if you have one specific injury and a limited budget: injectable BPC-157 at 500 mcg a day, or BPC-157 + TB-500, is where the money should go first. Not worth it for inflammatory arthritis (rheumatoid, psoriatic), which is an immune disease a tiny peptide will not reach. The alternatives listed here (Livagen, Ovagen, Prostamax, Vesugen) are sibling bioregulators for other organs, not substitutes for a joint.

What people use it for

Safety, in brief

The full picture — stop signs and who should talk to a doctor first — is on the dosing guide.

Sources

The labels and studies behind this page. Each link opens the original on PubMed, DailyMed or ClinicalTrials.gov.

1. The influence of peptides on the chondrogenic differentiation of human mesenchymal stem cells during replicative agingMyakisheva et al., Adv Gerontol 2023 · Study
2. Peptides prevent the forming of secretory phenotype of chondrocytes associated with the agingMyakisheva et al., Adv Gerontol 2023 · Study
3. Chondrocytes secretory phenotype associated with aging: role in the pathogenesis of osteoarthritis and prospects for peptide bioregulationMyakisheva et al., Adv Gerontol 2023 · Review